Source: http://www.outins.com/publications/
Timestamp: 2019-04-22 10:07:06+00:00

Document:
Danese MD, Reyes CM, Gleeson ML, Halperin M, Skettino SL, Mikhael J. Estimating the Population Benefits and Costs of Rituximab Therapy in the United States From 1998-2013 Using Real-World Data. Med Care. 2016 Jan 12.
Lubeck DP, Danese MD, Duryea J, Halperin M, Tayama D, Elaine E, Lalla D, Grotta JC. Quality Adjusted Life Year Gains Associated with the Administration of Recombinant Tissue-type Plasminogen Activator for Treatment of Acute Ischemic Stroke: 1998-2011. Int J Stroke 2016.
Doan Q, Gillard P, Brashear A, Halperin M, Hayward E, Varon S, Lu J. Cost-effectiveness of onabotulinumtoxinA for the treatment of wrist and hand disability due to upper-limb post-stroke spasticity in Scotland. Eur J Neurol. 2013 May;20(5):773-80. doi: 10.1111/ene.12062. Epub 2012 Dec 24.
Griffiths RI, O’Malley CD, Herbert RJ, Danese MD. Misclassification of incident conditions using claims data: impact of varying the period used to exclude pre-existing disease. BMC Med Res Methodol. 2013 Mar 6;13:32. doi: 10.1186/1471-2288-13-32.
Griffiths RI, Danese MD, Gleeson ML, Valderas JM. Epidemiology and outcomes of previously undiagnosed diabetes in older women with breast cancer: an observational cohort study based on SEER-Medicare. BMC Cancer 2012, 12:613 doi:10.1186/1471-2407-12-613.
Weitz I, Sanz MA, Henry D, Schipperus M, Godeau B, Northridge K, Gleeson M, Danese M, Deuson R. A novel approach to the evaluation of bleeding-related episodes in patients with chronic immune thrombocytopenia. Curr Med Res Opin. 2012 May;28(5):789-96. Epub 2012 Apr 25.
Griffiths RI, Gleeson ML, Mikhael J, Dreyling M, Danese MD. Comparative Effectiveness and Cost of Adding Rituximab to First-Line Chemotherapy for Elderly Patients Diagnosed with Diffuse Large B-Cell Lymphoma. Cancer, 2012.
Griffiths RI, Gleeson ML, Danese MD, O’Hagan A. Inverse Probability Weighted Least Squares Regression in the Analysis of Time-Censored Cost Data: An Evaluation of the Approach Using SEER-Medicare. Value Health. 2012 Jul;15(5):656-63. Epub 2012 Jun 22.
Griffiths RI, Gleeson ML, Mikhael J, Danese MD. Cost and Cost-Effectiveness of Adding Rituximab to First-Line Chemotherapy for Follicular Lymphoma (FL) in Elderly Patients: An Observational Cohort Study Based on SEER-Medicare. J Cancer Epidemiol. 2012.
hemodialysis with moderate to severe secondary hyperparathyroidism receiving combined therapy with cinacalcet and low-dose vitamin D sterols. Hemodial Int. 2011 Nov 28. doi: 10.1111/j.1542-4758.2011.00642.x.
Griffiths RI, Newsome BB, Leung G, Block GA, Herbert RJ, Danese MD. Impact of Hemodialysis Catheter Dysfunction on Dialysis and Other Medical Services: An Observational Cohort Study. Int J Nephrol. 2012;2012:376128.
Danese MD, Lindquist K, Doan J, Lalla D, Brammer M, Griffiths RI. Effect of Central Nervous System Metastases on Treatment Discontinuation and Survival in Older Women Receiving Trastuzumab for Metastatic Breast Cancer. J Cancer Epidemiol. 2012.
Griffiths RI, Barron RL, Gleeson ML, Danese MD, O’Hagan A, Chia VM, Legg JC, Lyman GH. Granulocyte-colony stimulating factor use and medical costs after initial adjuvant chemotherapy in older patients with early-stage breast cancer. PharmacoEconomics. 2012;30(2):103-118.
Griffiths R, Mikhael J, Gleeson M, Danese M, Dreyling M. Addition of Rituximab to Chemotherapy Alone as First-Line Therapy Improves Overall Survival in Elderly Patients with Mantle Cell Lymphoma. Blood, 2011;118(18):4808-4816.
Griffiths RI, Newsome BB, Block GA, Herbert RJ, Danese MD. Patterns of Hemodialysis Catheter Dysfunction Defined According to National Kidney Foundation Guidelines As Blood Flow <300 mL/min. Int J Nephrol. 2011;2011:891259. Epub 2011 Dec 8.
Griffiths RI, Lalla D, Herbert RJ, Doan JF, Brammer MG, Danese MD.Infused therapy and survival in older patients diagnosed with metastatic breast cancer who received trastuzumab. Cancer Invest. 2011 Nov;29(9):573-84.
Chertow GM, Lu ZJ, Xu X, Knight TG, Goodman WG, Bushinsky DA, Block GA. Self-reported symptoms in patients on hemodialysis with moderate to severe secondary hyperparathyroidism receiving combined therapy with cinacalcet and low-dose vitamin D sterols. Hemodial Int. 2011 Nov 28. doi: 10.1111/j.1542-4758.2011.00642.x.
Kilpatrick, R., Danese, M.D., Belozeroff V., Smirnakis K., Goodman, B., Rothman KJ. The association of vitamin D use with hypercalcemia and hyperphosphatemia in hemodialysis patients: a case-crossover study. Pharmacoepidemiol Drug Saf. 2011 Sep;20(9):914-21. doi: 10.1002/pds.2183.
M. Danese, R. Griffiths, M. Gleeson, S. Satram-Hoang, K. B. Knopf, J. Mikhael, C. M. Reyes. An observational study of outcomes after initial infused therapy in Medicare patients diagnosed with chronic lymphocytic leukemia. Blood. 2011 Mar 31;117(13):3505-13. Epub 2010 Dec 29.
Lindquist, K., Danese, M. D., Mikhael, J., Knopf, K. B., Griffiths, R. I. Health Care Utilization and Mortality Among Elderly Patients With Myelodysplastic Syndromes. Ann Oncol. 2011 May;22(5):1181-8. Epub 2010 Nov 1.
Shireman TI, Almehmi A, Wetmore JB, Lu ZJ, Pregenzer M, and Quarles LD. Economic analysis of cinacalcet in combination with low-dose vitamin D versus flexible dose vitamin D in treating secondary hyperparathyroidism in hemodialysis patients. Am J Kidney Dis. 2010 Dec;56(6):1108-16. Epub 2010 Oct 15.
Griffiths R, Gleeson M, Reyes C, Knopf K, Danese M. Survival in elderly follicular lymphoma patients who receive frontline chemo-immunotherapy. Am J Hematol. 2010 Dec;85(12):963-7.
Griffiths R, Gleeson M, Knopf K, Danese M. Racial differences in treatment and survival in older patients with diffuse large B-cell lymphoma (DLBCL). BMC Cancer. 2010 Nov 12;10:625.
Colwell HH, Mathias SD, Turner MP, Lu J, Wright N, Peeters M, Cella D, Devercelli G. Psychometric evaluation of the FACT Colorectal Cancer Symptom Index (FCSI-9): reliability, validity, responsiveness, and clinical meaningfulness. Oncologist. 2010;15(3):308-16. Epub 2010 Feb 26.
Mikhael J, Northridge K, Lindquist K, Kessler C, Deuson R, Danese M. Short-term and long-term failure of laparoscopic splenectomy in adult immune thrombocytopenic purpura patients: a systematic review. Am J Hematol. 2009 Nov;84(11):743-8.
Danese MD, Lindquist K, Gleeson M, Deuson R, Mikhael J. Cost and mortality associated with hospitalizations in patients with immune thrombocytopenic purpura. Am J Hematol. 2009 Oct;84(10):631-5.
Quan V Doan, Stephen M Lange, Adam Elfant, Daniel Aguilar, Eileen Reyes, Richard B Lynn, Robert W Dubois. Disease-specific cost savings of treating nighttime versus daytime gastroesophageal reflux disease in an employed population. JME. 2009. 11: 23-40.
Marcocci C, Chanson P, Shoback D, Bilezikian J, Fernandez-Cruz L, Orgiazzi J, Henzen C, Cheng S, Sterling LR, Lu J, Peacock M. Cinacalcet reduces serum calcium concentrations in patients with intractable primary hyperparathyroidism. J Clin Endocrinol Metab. 2009 Aug;94(8):2766-72. Epub 2009 May 26.
Thein M, Ershler WB, Artz AS, Tecson J, Robinson BE, Rothstein G, Liede A, Gylys-Colwell I, Lu ZJ, Robbins S. Diminished quality of life and physical function in community-dwelling elderly with anemia. Medicine (Baltimore). 2009 Mar;88(2):107-14.
Lalani T, Chu VH, Grussemeyer CA, Reed SD, Bolognesi MP, Friedman JY, Griffiths RI, Crosslin DR, Kanafani ZA, Kaye KS, Ralph Corey G, Fowler VG Jr. Clinical Outcomes and Costs Among Patients with Staphylococcus Aureus Bacteremia and Orthopedic Device Infections. Scand J Infect Dis, 2008;40(11-12):973-7.
Sprague, S. M., Belozeroff, V., Danese, M. D., Martin, L. P., & Olgaard, K. Abnormal bone and mineral metabolism in kidney transplant patients–a review. Am.J.Nephrol. 2008. 28: 246-253.
Pinto, L., Liu, Z., Doan, Q., Bernal, M., Dubois, R., & Lyman, G. Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials. Curr.Med.Res.Opin. 2007. 23: 2283-2295.
Doan, Q. V., Gleeson, M., Kim, J., Borker, R., Griffiths, R., & Dubois, R. W. Economic burden of cardiovascular events and fractures among patients with end-stage renal disease. Curr.Med.Res.Opin. 2007. 23: 1561-1569.
Liu, Z., Doan, Q. V., Blumenthal, P., & Dubois, R. W. A systematic review evaluating health-related quality of life, work impairment, and health-care costs and utilization in abnormal uterine bleeding. Value.Health. 2007. 10: 183-194.
Yu, H. T., Dylan, M. L., Lin, J., & Dubois, R. W. Hospitals’ compliance with prophylaxis guidelines for venous thromboembolism. Am.J.Health Syst.Pharm. 2007. 64: 69-76.
Colwell HH, Mathias SD, Ngo NH, Gitlin M, Lu ZJ, Knoop T. The impact of infusion reactions on oncology patients and clinicians in the inpatient and outpatient practice settings: oncology nurses’ perspectives. J Infus Nurs. 2007 May-Jun;30(3):153-60.
Vera-Llonch M, Oster G, Ford CM, Lu J, Sonis S. Oral mucositis and outcomes of autologous hematopoietic stem-cell transplantation following high-dose melphalan conditioning for multiple myeloma. J Support Oncol. 2007 May;5(5):231-5.
Vera-Llonch M, Oster G, Ford CM, Lu J, Sonis S. Oral mucositis and outcomes of allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies. Support Care Cancer. 2007 May;15(5):491-6. Epub 2006 Dec 1.
Chiou, C. F., Suarez-Almazor, M. E., Sherbourne, C. D., Chang, C. H., Reyes, C., Dylan, M, Ofman, J., Wallace, D. J., Mizutani, W., & Weisman, M. Development and validation of a preference weight multiattribute health outcome measure for rheumatoid arthritis. J.Rheumatol. 2006. 33: 2409-2411.
Doan, Q. V., Chiou, C. F., & Dubois, R. W. Review of eight pharmacoeconomic studies of the value of biologic DMARDs (adalimumab, etanercept, and infliximab) in the management of rheumatoid arthritis. J.Manag.Care Pharm. 2006. 12: 555-569.
Stovsky, M. D., Griffiths, R. I., & Duff, S. B. A clinical outcomes and cost analysis comparing photoselective vaporization of the prostate to alternative minimally invasive therapies and transurethral prostate resection for the treatment of benign prostatic hyperplasia. J.Urol. 2006. 176: 1500-1506.
Danese, M. D., Liu, Z., Griffiths, R. I., Dylan, M., Yu, H. T., Dubois, R., & Nissenson, A. R. Catheter use is high even among hemodialysis patients with a fistula or graft. Kidney Int. 2006. 70: 1482-1485.
Cappola, A. R., Fried, L. P., Arnold, A. M., Danese, M. D., Kuller, L. H., Burke, G. L., Tracy, R. P., & Ladenson, P. W. Thyroid status, cardiovascular risk, and mortality in older adults. JAMA. 2006. 295: 1033-1041.
Chiou, C. F., Sherbourne, C. D., Cornelio, I., Lubeck, D. P., Paulus, H. E., Dylan, M., & Weisman, M. Revalidation of the original Cedars-Sinai health-related quality of life in rheumatoid arthritis questionnaire. J.Rheumatol. 2006. 33: 256-262.
Danese, M. D., Griffiths, R. I., Dylan, M., Yu, H. T., Dubois, R., & Nissenson, A. R. Mortality differences among organisms causing septicemia in hemodialysis patients. Hemodial.Int. 2006. 10: 56-62.
Chu, V. H., Crosslin, D. R., Friedman, J. Y., Reed, S. D., Cabell, C. H., Griffiths, R. I., Masselink, L. E., Kaye, K. S., Corey, G. R., Reller, L. B., Stryjewski, M. E., Schulman, K. A., & Fowler, V. G., Jr. Staphylococcus aureus bacteremia in patients with prosthetic devices: costs and outcomes. Am.J.Med. 2005. 118: 1416.
Danese, M. D., Kim, J., Doan, Q. V., Dylan, M., Griffiths, R., & Chertow, G. M. PTH and the risks for hip, vertebral, and pelvic fractures among patients on dialysis. Am.J.Kidney Dis. 2006. 47: 149-156.
Patrick J. Stiff, Christos Emmanouilides, William I. Bensinger, Teresa Gentile, Bruce Blazar, Thomas C. Shea, John Lu, John Isitt, Alessandra Cesano, Ricardo Spielberger. Palifermin Reduces Patient-Reported Mouth and Throat Soreness and Improves Patient Functioning in the Hematopoietic Stem-Cell Transplantation Setting.Journal of Clinical Oncology, Vol 24, No 33 (November 20), 2006: pp. 5186-5193.
Stiff PJ, Erder H, Bensinger WI, Emmanouilides C, Gentile T, Isitt J, Lu ZJ, Spielberger R. Reliability and validity of a patient self-administered daily questionnaire to assess impact of oral mucositis (OM) on pain and daily functioning in patients undergoing autologous hematopoietic stem cell transplantation (HSCT)..Bone Marrow Transplant. 2006 Feb;37(4):393-401.
Chiou, C. F., Weisman, M., Sherbourne, C. D., Reyes, C., Dylan, M, Ofman, J., Wallace, D. J., Mizutani, W., & Suarez-Almazor, M. E. Measuring preference weights for American college of rheumatology response criteria for patients with rheumatoid arthritis. J.Rheumatol. 2005. 32: 2326-2329.
Cunningham, J., Danese, M., Olson, K., Klassen, P., & Chertow, G. M. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int. 2005. 68: 1793-1800.
Nissenson, A. R., Dylan, M. L., Griffiths, R. I., Yu, H. T., Dean, B. B., Danese, M. D., & Dubois, R. W. Clinical and economic outcomes of Staphylococcus aureus septicemia in ESRD patients receiving hemodialysis. Am.J.Kidney Dis. 2005. 46: 301-308.
Engemann, J. J., Friedman, J. Y., Reed, S. D., Griffiths, R. I., Szczech, L. A., Kaye, K. S., Stryjewski, M. E., Reller, L. B., Schulman, K. A., Corey, G. R., & Fowler, V. G., Jr. Clinical outcomes and costs due to Staphylococcus aureus bacteremia among patients receiving long-term hemodialysis. Infect.Control Hosp.Epidemiol. 2005. 26: 534-539.
Dean, B. B., Dylan, M, Gano, A., Jr., Knight, K., Ofman, J. J., & Levine, B. S. Erythropoiesis-stimulating protein therapy and the decline of renal function: a retrospective analysis of patients with chronic kidney disease. Curr.Med.Res.Opin. 2005. 21: 981-987.
Brecht, M. L., Anglin, M. D., & Dylan, M. Coerced treatment for methamphetamine abuse: differential patient characteristics and outcomes. Am.J.Drug Alcohol Abuse. 2005. 31: 337-356.
Reed, S. D., Friedman, J. Y., Engemann, J. J., Griffiths, R. I., Anstrom, K. J., Kaye, K. S., Stryjewski, M. E., Szczech, L. A., Reller, L. B., Corey, G. R., Schulman, K. A., & Fowler, V. G., Jr. Costs and outcomes among hemodialysis-dependent patients with methicillin-resistant or methicillin-susceptible Staphylococcus aureus bacteremia. Infect.Control Hosp.Epidemiol. 2005. 26: 175-183.
Haithcox S, R Ramnes C, Lee H, Lu J, Lyman GH.The impact of frequent injections for hematopoietic growth factor support on patients receiving chemotherapy: an observational study. BMC Nurs. 2003 Sep 19;2(1):2.
Lee, V. C., Rhew, D. C., Dylan, M, Badamgarav, E., Braunstein, G. D., & Weingarten, S. R. Meta-analysis: angiotensin-receptor blockers in chronic heart failure and high-risk acute myocardial infarction. Ann.Intern.Med. 2004. 141: 693-704.
B. Standert, J. Goldstone, Z J Lu, and H. Erder, and JA Liu Yin. Estimating AML treatment cost in the UK: results of a randomized trial with and without filgrastim use. Pharmacoeconomics June 2002; 20(10): 665-674.
Griffiths, R. I., Bar-Din, M., MacLean, C. H., Sullivan, E. M., Herbert, R. J., & Yelin, E. H. Medical resource use and costs among rheumatoid arthritis patients receiving disease-modifying antirheumatic drug therapy. Arthritis Care Res. 2000. 13: 213-226.
Griffiths, R. I., Bar-Din, M., MacLean, C., Sullivan, E. M., Herbert, R. J., & Yelin, E. H. Patterns of disease-modifying antirheumatic drug use, medical resource consumption, and cost among rheumatoid arthritis patients. Ther.Apher. 2001. 5: 92-104.
Griffiths, R. I., Rabeneck, L., Guzman, G., Cromwell, D. M., Strauss, M. J., Robinson, J. W., Winston, B., Li, T., & Graham, D. Y. Costs of managing Helicobacter pylori-infected ulcer patients after initial therapy. Helicobacter. 2001. 6: 66-76.
Ayala AR, Danese MD, Ladenson PW. When to treat mild hypothyroidism. Endocrinol Metab Clin North Am. 2000 Jun;29(2):399-415.
Danese, M. D., Ladenson, P. W., Meinert, C. L., & Powe, N. R. Clinical review 115: effect of thyroxine therapy on serum lipoproteins in patients with mild thyroid failure: a quantitative review of the literature. J.Clin.Endocrinol.Metab. 2000. 85: 2993-3001.
Meyer, C. M., Ladenson, P. W., Scharfstein, J. A., Danese, M. D., & Powe, N. R. Evaluation of common problems in primary care: effects of physician, practice, and financial characteristics. Am.J.Manag.Care. 2000. 6: 457-469.
Sullivan, E. M., Griffiths, R. I., Frank, R. G., Strauss, M. J., Herbert, R. J., Clouse, J., & Goldman, H. H. One-year costs of second-line therapies for depression. J.Clin.Psychiatry. 2000. 61: 290-298.
Griffiths, R. I., Sullivan, E. M., Frank, R. G., Strauss, M. J., Herbert, R. J., Clouse, J., & Goldman, H. H. Medical resource use and cost of venlafaxine or tricyclic antidepressant therapy. Following selective serotonin reuptake inhibitor therapy for depression. Pharmacoeconomics. 1999. 15: 495-505.
Olin, J. W., Beusterien, K. M., Childs, M. B., Seavey, C., McHugh, L., & Griffiths, R. I. Medical costs of treating venous stasis ulcers: evidence from a retrospective cohort study. Vasc.Med. 1999. 4: 1-7.
Griffiths, R. I., Schrammel, P. N., Morris, G. L., Wills, S. H., Labiner, D. M., & Strauss, M. J. Payer costs of patients diagnosed with epilepsy. Epilepsia. 1999. 40: 351-358.
Schrammel, P., Griffiths, R. I., & Griffiths, C. B. A workplace breast cancer screening program. Costs and components. AAOHN.J. 1998. 46: 523-529.
Estroff, S. E., Swanson, J. W., Lachicotte, W. S., Swartz, M., & Bolduc, M. Risk reconsidered: targets of violence in the social networks of people with serious psychiatric disorders. Soc.Psychiatry Psychiatr.Epidemiol. 1998. 33 Suppl 1: S95-101.
Griffiths, R. I., Hyman, C. L., McFarlane, S. I., Saurina, G. R., Anderson, J. E., O’Brien, T., Popper, C., McGrath, M. M., Herbert, R. J., & Sierra, M. F. Medical-resource use for suspected tuberculosis in a New York City hospital. Infect.Control Hosp.Epidemiol. 1998. 19: 747-753.
Snyder, C., Schrammel, P. N., Griffiths, C. B., & Griffiths, R. I. Prostate cancer screening in the workplace. Employer costs. AAOHN.J. 1998. 46: 379-384.
Lu ZJ, Comanor, W. S. Strategic Pricing of New Pharmaceuticals. The Review of Economics and Statistics, Vol. 80, No. 1 (Feb., 1998), pp. 108-118.
Glick HA, Shpall EJ, LeMaistre CF, McCarron TJ, Lu ZJ, Erder MH, Glaspy JA. Empirical Criteria for the Selection of Quality-of-life Instruments for the Evaluation of Peripheral Blood Progenitor Cell Transplantation. Int J Technol Assess Health Care. 1998 Summer;14(3):419-30.
Griffiths, R. I., Bleecker, G. C., Jabs, D. A., Dieterich, D. T., Coleson, L., Winters, D., Wolitz, R., & Steinberg, E. P. Pharmacoeconomic analysis of 3 treatment strategies for cytomegalovirus retinitis in patients with AIDS. Pharmacoeconomics. 1998. 13: 461-474.
Powe, N. R., Danese, M. D., & Ladenson, P. W. Decision analysis in endocrinology and metabolism. Endocrinol.Metab Clin.North Am. 1997. 26: 89-111.
Moore, R. D., Chaulk, C. P., Griffiths, R., Cavalcante, S., & Chaisson, R. E. Cost-effectiveness of directly observed versus self-administered therapy for tuberculosis. Am.J.Respir.Crit Care Med. 1996. 154: 1013-1019.
Dorsey, J. H., Holtz, P. M., Griffiths, R. I., McGrath, M. M., & Steinberg, E. P. Costs and charges associated with three alternative techniques of hysterectomy. N.Engl.J.Med. 1996. 335: 476-482.
Danese, M. D., Powe, N. R., Sawin, C. T., & Ladenson, P. W. Screening for mild thyroid failure at the periodic health examination: a decision and cost-effectiveness analysis. JAMA. 1996. 276: 285-292.
Griffiths, R. I., McGrath, M. M., & Vogel, V. G. Economic savings and costs of periodic mammographic screening in the workplace. Oncology (Williston.Park). 1996. 10: 285-289.
Powe, N. R. & Griffiths, R. I. The clinical-economic trial: promise, problems, and challenges. Control Clin.Trials. 1995. 16: 377-394.
Griffiths, R. I., Anderson, G. F., Powe, N. R., Oliveras, E., Herbert, R. J., Grant, C. C., & Davidson, B. L. Economic impact of immunization against rotavirus gastroenteritis. Evidence from a clinical trial. Arch.Pediatr.Adolesc.Med. 1995. 149: 407-414.
Griffiths, R. I., Powe, N. R., Greer, J., de Lissovoy, G., Anderson, G. F., Whelton, P. K., Watson, A. J., & Eggers, P. W. A review of the first year of Medicare coverage of erythropoietin. Health Care Financ.Rev. 1994. 15: 83-102.
Griffiths, R. I., Griffiths, C. B., & Powe, N. R. Simulated lifetime costs of three types of employer-based, periodic, breast cancer screening programs for working-age women. Am.J.Health Promot. 1994. 9: 137-146.
Griffiths, R. I., Powe, N. R., Gaskin, D. J., Anderson, G. F., de Lissovoy, G. V., & Whelton, P. K. The production of dialysis by for-profit versus not-for-profit freestanding renal dialysis facilities. Health Serv.Res. 1994. 29: 473-487.
Bass, E. B., Steinberg, E. P., Pitt, H. A., Griffiths, R. I., Lillemoe, K. D., Saba, G. P., & Johns, C. Comparison of the rating scale and the standard gamble in measuring patient preferences for outcomes of gallstone disease. Med.Decis.Making. 1994. 14: 307-314.
de Lissovoy, G., Powe, N. R., Griffiths, R. I., Watson, A. J., Anderson, G. F., Greer, J. W., Herbert, R. J., Eggers, P. W., Milam, R. A., & Whelton, P. K. The relationship of provider organizational status and erythropoietin dosing in end stage renal disease patients. Med.Care. 1994. 32: 130-140.
Powe, N. R., Griffiths, R. I., Watson, A. J., Anderson, G. F., de Lissovoy, G., Greer, J. W., Herbert, R. J., Milam, R. A., & Whelton, P. K. Effect of recombinant erythropoietin on hospital admissions, readmissions, length of stay, and costs of dialysis patients. J.Am.Soc.Nephrol. 1994. 4: 1455-1465.
Powe, N. R., Griffiths, R. I., Anderson, G. F., de Lissovoy, G., Watson, A. J., Greer, J. W., Herbert, R. J., & Whelton, P. K. Medicare payment policy and recombinant erythropoietin prescribing for dialysis patients. Am.J.Kidney Dis. 1993. 22: 557-567.
Bass, E. B., Powe, N. R., Goodman, S. N., Graziano, S. L., Griffiths, R. I., Kickler, T. S., & Wingard, J. R. Efficacy of immune globulin in preventing complications of bone marrow transplantation: a meta-analysis. Bone Marrow Transplant. 1993. 12: 273-282.
Griffiths, R. I., Bass, E. B., Powe, N. R., Anderson, G. F., Goodman, S., & Wingard, J. R. Factors influencing third party payer costs for allogeneic BMT. Bone Marrow Transplant. 1993. 12: 43-48.
Powe, N. R., Griffiths, R. I., Greer, J. W., Watson, A. J., Anderson, G. F., de Lissovoy, G., Herbert, R. J., Eggers, P. W., Milam, R. A., & Whelton, P. K. Early dosing practices and effectiveness of recombinant human erythropoietin. Kidney Int. 1993. 43: 1125-1133.
Powe, N. R., Griffiths, R. I., & Bass, E. B. Cost implications to Medicare of recombinant erythropoietin therapy for the anemia of end-stage renal disease. J.Am.Soc.Nephrol. 1993. 3: 1660-1671.
Powe, N. R., Griffiths, R. I., de Lissovoy, G., Anderson, G. F., Watson, A. J., Greer, J. W., Herbert, R. J., Eggers, P. W., Milam, R. A., & Whelton, P. K. Access to recombinant erythropoietin by Medicare-entitled dialysis patients in the first year after FDA approval. JAMA. 1992. 268: 1434-1440.

References: V. 
 V. 
 V. 
 V. 
 V. 
 V.